PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Fluorodopa→

Fluorodopa PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
92812-82-3
Molecular formula
C9H10FNO4
Molecular weight
215.18 g/mol
Drug class
Diagnostic radiopharmaceuticalpositron-emission tomography (PET) dopaminergic imaging agent
Mechanism of action
Fluorodopa F 18 enters dopaminergic nerve terminals via amino-acid transport and is decarboxylated by aromatic L-amino-acid decarboxylase to fluorodopamine F 18, which is retained in presynaptic vesicles. Striatal accumulation is visualised by PET.
Indications / reported uses
  • PET imaging of striatal dopaminergic nerve terminals as an adjunct in the evaluation of adults with suspected parkinsonian syndromes.

Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=262503e7-de09-4b42-9963-ec00cbc7c35c · https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212041s000lbl.pdf

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Fluorodopa PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Fluorodopa Permitted Daily Exposure (PDE) report (the Fluorodopa PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Fluorodopa Occupational Exposure Limit (OEL) report (the Fluorodopa OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.